In patients diagnosed with chronic migraine and medication-overuse headache (MOH), treatment with eptinezumab led to improved patient-reported outcomes, fewer migraine days, and a reduction in acute medication use, according to subgroup analyses of the PROMISE-2* trial presented at AHS 2020.
A single oral dose of rimegepant offers rapid, sustained pain relief for the acute treatment of migraine, thus allowing early return to normal function without the need for repeat dosing or rescue medications, results of three phase III studies presented at the AHS 2020 Meeting have shown.
Ubrogepant sustains its favourable effect for migraine regardless of demographic and clinical features, and concomitant medication use, according to pooled results of the ACHIEVE I and II studies presented at AHS 2020.
Long-term use of onabotulinumtoxinA led to reductions in monthly headache days (MHDs) in adults with chronic migraine (CM), according to post hoc analyses of the COMPEL* study presented at the AHS 2020 virtual scientific meeting.
After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.